SCHEMBL3038155

SCHEMBL3038155

CCn1nc(-c2ccncc2)c(C(=O)CCc2ccccc2)c(Nc2cccc(C(N)=O)c2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.49
BUB1 O43683 2/20 0.41
TP53 P04637 1/20 0.38
ROCK2 O75116 4/20 0.37
GRK2 P25098 4/20 0.37
PRKCA P17252 3/20 0.37
GRK3 P35626 2/20 0.37
GRK5 P34947 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
GRK7 Q8WTQ7 1/20 0.36
KDM4E B2RXH2 1/20 0.35
SRC P12931 1/20 0.35
BRAF P15056 1/20 0.35
KDR P35968 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032987 0.86 PDE4B (0.60) PDE4BBUB1TP53GRK2GRK3
SCHEMBL1652996 0.84 PDE4B (0.40) PDE4BTP53KDM4EMAPTSMN1; SMN2
SCHEMBL4705601 0.83 PDE4B (0.53) PDE4BKDM4EMAPTSMN1; SMN2
SCHEMBL3038578 0.83 PDE4B (0.55) PDE4BTP53KDM4EMAPTSMN1; SMN2
SCHEMBL4706065 0.82 PDE4B (0.70) PDE4BTP53MAPKAPK2KDRMAPT
SCHEMBL4708499 0.81 PDE4B (0.51) PDE4BTP53SMN1; SMN2ADORA2AADORA1
SCHEMBL4708911 0.80 PDE4B (0.49) PDE4BPRKCAKDRMAPTADORA2A
SCHEMBL4674510 0.80 PDE4B (0.69) PDE4BBUB1KDM4ESMN1; SMN2
SCHEMBL4707424 0.80 PDE4B (0.75) PDE4BTP53SMN1; SMN2ADORA1
SCHEMBL4708616 0.79 PDE4B (0.55) PDE4BTP53SMN1; SMN2ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2010-08-12 US claimed
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2009-04-30 US claimed
US-7491722-B2 Pyridazin-3(2H)-one derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-02-17 US claimed
EP-1575926-B1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES ALMIRALL LAB (ES) 2008-03-05 EP claimed
US-20060173008-A1 New pyridazin-3(2h)-one derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2006-08-03 US claimed
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2010-08-12 US disclosed
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES LABORATORIOS ALMIRALL, S. A. 2009-04-30 US disclosed
US-7491722-B2 Pyridazin-3(2H)-one derivatives LABORATORIOS ALMIRALL S.A. (ES) 2009-02-17 US disclosed
EP-1575926-B1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES ALMIRALL LAB (ES) 2008-03-05 EP disclosed
US-20060173008-A1 New pyridazin-3(2h)-one derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111819-A1 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B PDE4B 5/4885BUB1 4122/4885TP53 4760/4885
US-20060173008-A1 New pyridazin-3(2h)-one derivatives PDE3A, PDE4A, PDE3B PDE4B 4/4885BUB1 4333/4885TP53 4770/4885
US-20100204241-A9 NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES PDE4A, PDE3A, PDE3B PDE4B 5/4885BUB1 4122/4885TP53 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.